Abbott Laboratories (ABT) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pac...
Abbott Laboratories (ABT) currently trades at a P/E ratio of 30.95 (historical range: 12.74–42.50, median: 17.87), placing it at the 69th percentile — above its historical average, P/S ratio of 4.30 (range: 3.20–5.95, 21th percentile — below its historical average), EV/EBITDA of 161.03 (range: 22.23–168.12, 98th percentile).
Over the historical period (2024-08-30 to 2026-08-28), Abbott Laboratories's P/E ratio has contracted by 28% over the observed period (from an average of 28.2 to 20.2).
Abbott Laboratories appears slightly overvalued relative to its historical range, with most valuation metrics above their median levels.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 30.95 | 12.74 | 17.87 | 42.50 | 69th | above its historical average |
| P/S Ratio | 4.30 | 3.20 | 4.98 | 5.95 | 21th | below its historical average |
| EV/EBITDA | 161.03 | 22.23 | 59.27 | 168.12 | 98th | expensive relative to its history |
| FCF Yield | 0.00 | 0.00 | 0.01 | 0.04 | 14th | expensive relative to its history |